ResMed (RMD)
Health Care · medical devices and health software · NYSE
ResMed is a leading provider of AI-powered, cloud-connected medical devices and software that revolutionize the management of sleep apnea and chronic respiratory conditions at home.
What ResMed does
ResMed is a global digital health company that designs and manufactures cloud-connected medical devices and software solutions for the treatment of sleep apnea, respiratory disorders, and other chronic diseases. The company provides a comprehensive portfolio, including CPAP machines, masks, ventilation devices, and diagnostic services, alongside management software for healthcare providers in residential, hospice, and home health care settings. By integrating AI-powered analytics and remote monitoring, ResMed aims to improve patient therapy adherence and reduce costs for healthcare systems worldwide.
Themes: digital health / remote patient monitoring, sleep health / obstructive sleep apnea, respiratory care / ventilation, healthcare IT / software solutions, AI in healthcare
Fundamentals
- Price$231.52 as of 2026-08-21 close
- Market cap$33.4B as of 2026-08-21
- 1-year return-19.7% 2025-08-21 close $288.34 → 2026-08-21 close $231.52
- P/E21.47 as of 2026-08-24
- Net margin+26.9% as of 2026-08-24
- Gross margin+61.1% as of 2026-08-24
- ROE+23.9% as of 2026-08-24
- Debt / equity0.10 as of 2026-08-24
- Revenue growth (YoY)+9.8% as of 2026-08-24
- Revenue CAGR (3y)+12.9% SEC XBRL
- Beta0.74 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.2%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How RMD compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RMD is in the Health Care Long-term Top 10.
Health Care Long-term Top 10 — since 18 Aug 2026
Long-term score
63.8 #105 of 987 scored · #4 of 57 in Health Care
Financial health 88th (debt to equity 0.1, free cash flow margin 28.8%) and profitability 78th (operating margin 33.4%, return on equity 23.9%); weakest is long-term trend (28th, a "death cross" — its 50-day average is below its 200-day).
Short-term score
49.2 #843 of 1,704 scored · #146 of 240 in Health Care
Volume and participation 88th: trading volume is about normal versus its 30-day average; trend 64th: the price is 9% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is catalysts 29th: analysts have cut their average price target by 0.5% since the prior reading. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
In this list since 18 Aug 2026 — currently 4th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 2, score 65.3.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, RMD's dividend was covered by reported results (earnings payout 22%, free-cash-flow payout 19%). This describes past coverage, not a forecast.
- Earnings payout22% dividends / net income
- Free-cash-flow payout19% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How ResMed looks technically
ResMed (RMD) is trading 0.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 165 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-03-17, pushing above its recent trading range. It is 21.2% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 0.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $206.94 | $206.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $229.66 | $229.66 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 190.21. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 165 trading days ago — a "death cross", a bearish long-term signal | 165 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.8% above | +0.8% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 17.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($202.00 to $234.14) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 91.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $293.81 | $293.81 |
|---|---|---|
| From the 52-week high | it is 21.2% below its 52-week high (its highest price of the past year) | -21.2% |
| Above the 52-week low | it is 28.4% above its 52-week low (its lowest price of the past year) | +28.4% |
| Below the 52-week high | it is 21.2% below its highest point of the past year | 21.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-03-17, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-03-17, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $301.19 (set on 2021-09-09) | $301.19 |
| Given back of the 52-week move | over the past year its closes ranged ($182.82 to $293.73), and it has recovered roughly a third of its fall from last year’s high — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $251.36 to $254.91. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.9% |
| From the all-time high | it is 23.1% below its all-time high | -23.1% |
| Nearest price level | it is sitting right on a support level at $231.42 — a price it turned at four times since 2024-09-18, most recently on 2026-03-25. Since 2024-08-21 it has 5 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.0% |
| All-time low | its lowest closing price on record is $14.45 (set on 2008-10-28) | $14.45 |
| Above the all-time low | it is 1502.2% above its all-time low | +1,502% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.07 between its high and its low — about 3.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.07 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $204.21 and $235.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $204.21 – $219.82 – $235.44 |
| Typical daily range (% of price) | its price moves about 3.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (0.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.31× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.5% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.4% |
|---|---|---|
| Gap filled | a 7.2% gap down opened on 2026-08-07 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 15.9 percentage points (the stock gained 18.2% while the market gained 2.3%) | +15.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.7 percentage points (the stock gained 10.8% while the market gained 3.1%) | +7.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 21.7 percentage points (the stock lost 10.7% while the market gained 11.1%) | -21.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 40.2 percentage points (the stock lost 19.7% while the market gained 20.5%) | -40.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.6% of the share price, which is taken to mean a barrier that gives way easily. | +13.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $221.26 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +4.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-07-07 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $213.37 — a volume-weighted average of daily closes over 34 sessions, not a true tick-by-tick VWAP. | +8.5% |
Price levels it has turned at before
RMD last closed at $231.52 on 2026-08-21. Since 2024-08-21 it has turned at 5 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $231.42 | Support | at the last close | turned there four times · 2024-09-18 to 2026-03-25 |
| $225.15 | Support | 2.8% below the last close | turned there four times · 2024-12-23 to 2026-07-06 |
| $238.96 | Resistance | 3.2% above the last close | turned there 11 times · 2024-10-23 to 2026-04-08 |
| $217.66 | Support | 6.0% below the last close | turned there three times · 2025-03-13 to 2026-03-30 |
| $245.40 | Resistance | 6.0% above the last close | turned there 7 times · 2024-10-15 to 2026-02-12 |
| $253.11 | Resistance | 9.3% above the last close | turned there 10 times · 2024-09-09 to 2026-02-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $190.21.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $232.38 and $258.43 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $190.21.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.42 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$245.50 range $175.00 – $320.00; median $235.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RMD
- Consensus EPS estimate$2.69 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on continuous positive airway pressure (CPAP) and sleep therapy market trends.","Complex regulatory landscape and quality/compliance requirements for medical devices.","Risks associated with international operations and global supply chain dependencies."]
What changed in the latest 10-Q
AI-assisted comparison of RMD's 10-Q filed 2026-05-01 against the prior one filed 2026-01-30.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Period reference changed from 'three and six months ended December 31, 2025' (filed 2026-01-30) to 'three and nine months ended March 31, 2026' (filed 2026-05-01)
- R&D investment amount changed from '$91.0 million' (filed 2026-01-30) to '$94.3 million' (filed 2026-05-01)
- R&D as percentage of net revenues changed from '6.4%' (filed 2026-01-30) to '6.6%' (filed 2026-05-01)
- Period reference for R&D investment changed from 'three months ended December 31, 2025' (filed 2026-01-30) to 'three months ended March 31, 2026' (filed 2026-05-01)
- Notes:
- Both texts are truncated at the end; comparison is limited to complete passages available
- Forward-Looking Statements section is identical between filings
- Company description and business overview sections are substantively identical except for period and R&D figures
Risk Factors
- Added:
- Added new financial data for March 31, 2026 period in balance sheet (newer filing dated 2026-05-01)
- Added three months ended March 31, 2026 and nine months ended March 31, 2026 comparative periods in statements of operations (newer filing)
- Added three months ended March 31, 2026 and nine months ended March 31, 2026 comparative periods in comprehensive income statement (newer filing)
- Added equity statement rows for quarter ended March 31, 2026 with stock option exercises, RSU vesting, stock-based compensation, treasury stock purchases, and other comprehensive income items (newer filing)
- Restructuring expenses line item shows $21,745 for nine months ended March 31, 2026 in newer filing vs. $21,745 for six months ended December 31, 2025 in older filing
- Removed:
- Removed December 31, 2025 balance sheet comparison date (replaced with March 31, 2026 in newer filing)
- Removed three months ended December 31, 2025 and six months ended December 31, 2025 periods from statements of operations (replaced with three and nine months ended March 31, 2026)
- Removed three months ended December 31, 2025 and six months ended December 31, 2025 periods from comprehensive income statement (replaced with three and nine months ended March 31, 2026)
- Removed equity statement data for December 31, 2025 balance and removed the separate continuation page showing balance as of December 31, 2025
- Reworded:
- Risk Factors page number changed from 41 to 42 in table of contents (newer filing)
- Unregistered Sales page number changed from 41 to 42 (newer filing)
- Defaults Upon Senior Securities page number changed from 41 to 42 (newer filing)
- Mine Safety Disclosures page number changed from 41 to 42 (newer filing)
- Other Information page number changed from 41 to 42 (newer filing)
- Exhibits page number changed from 43 to 44 (newer filing)
- Signatures page number changed from 44 to 45 (newer filing)
- Comparison period label changed from 'December 31, 2025' to 'March 31, 2026' in balance sheet (newer filing)
- Notes:
- The newer filing contains forward-looking financial data for Q3 fiscal 2026 (ended March 31, 2026) while older filing presented Q2 fiscal 2026 (ended December 31, 2025) data
- Comparison years differ: newer filing compares 2026 vs. 2025 periods; older filing compared 2025 vs. 2024 periods
- Detailed equity statement continuation page appears truncated in both filings at the same point, limiting full comparison of that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($3M) — 2 selling insiders
- Last 90 days0 buys · 4 sells ($5M) — 2 selling insiders
- Last 180 days0 buys · 11 sells ($10M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 6 matched disclosures for RMD from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding RMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,540,173
- Reported value $4,386,378,109
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RMD had 15,676,616 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RMD had 10.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.19 days to cover at the same settlement.
- Reported short interest (shares) 15,676,616
- Short interest (% of shares outstanding) 10.9%
- Prior settlement (shares) 13,541,103
- Reported change 15.77%
- Days to cover (reported) 14.19
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Philips Healthcare (PHG)
- Fisher & Paykel Healthcare (FPH)
- Inspire Medical Systems (INSP)
- Medtronic (MDT)
- Drive DeVilbiss Healthcare
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RMD vs…
ResMed is found in…
Frequently asked questions
What does ResMed (RMD) do?
ResMed is a global digital health company that designs and manufactures cloud-connected medical devices and software solutions for the treatment of sleep apnea, respiratory disorders, and other chronic diseases. The company provides a comprehensive portfolio, including CPAP machines, masks, ventilation devices, and diagnostic services, alongside management software for healthcare providers in residential, hospice, and home health care settings.
What sector is ResMed (RMD) in?
ResMed (RMD) is classified in the Health Care sector. Its industry is medical devices and health software. It trades on NYSE.
Does RMD pay a dividend?
Yes — ResMed (RMD) pays a dividend, with an indicated yield of about 1.25% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are ResMed's (RMD) competitors?
Notable peers of ResMed (RMD) include Philips Healthcare, Fisher & Paykel Healthcare, Inspire Medical Systems, Medtronic and Drive DeVilbiss Healthcare. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in RMD?
Yes — we hold 6 matched STOCK Act disclosures for RMD from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ResMed (RMD) overbought or oversold right now?
ResMed (RMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.